Brief: 60 Degrees Pharma Announces IRB Approval Of Phase IIA Study To Evaluate Tafenoquine For Babesiosis, Type C Meeting Re-Scheduled By FDA To January 17 2024
26/12/2023 13:13
Dec 26 (Reuters) - 60 Degrees Pharmaceuticals Inc
SXTP.O :
* 60 DEGREES PHARMA ANNOUNCES IRB APPROVAL OF PHASE IIA
STUDY TO
EVALUATE TAFENOQUINE FOR BABESIOSIS, AN EMERGING TICK-BORNE
DISEASE; TYPE C MEETING RE-SCHEDULED BY FDA TO JANUARY 17, 2024
Source text for Eikon: ID:nGNX1W8yc9
Further company coverage: SXTP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM